COMMUNIQUÉS West-GlobeNewswire

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
01/04/2024
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a [...]
HNL Lab Medicine Unveils Lifesaving Cellular Therapy Laboratory
01/04/2024
ALLENTOWN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- HNL Lab Medicine, a leader in comprehensive laboratory services, proudly announces the grand opening of a state-of-the art Cellular Therapy Laboratory, made possible by [...]
BioSyent to Present at LD Micro New York Investor Conference
01/04/2024
MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the [...]
Applied UV, Inc. Announces Closing of $2.76 Million Registered Direct and Private Placement
01/04/2024
NEW YORK, NY, April 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Applied UV, Inc. (NASDAQ: AUVI) (the “Company”), a leader in smart building technology solutions, today announced the closing of its previously [...]
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
01/04/2024
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. ( [...]
Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024
01/04/2024
LAKEWOOD, Colo., April 01, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at [...]
SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers
01/04/2024
CHINO HILLS, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous [...]
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
01/04/2024
BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation [...]
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
01/04/2024
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE [...]
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
01/04/2024
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both [...]
Assertio to Present at LD Micro Invitational Conference in New York City
01/04/2024
LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated [...]
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
01/04/2024
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. After [...]
Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer
01/04/2024
Experienced Burn Industry Executive Champions Pivot to Commercialization DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) [...]
UpHealth Holdings Takes Steps to Enforce the International Court of Arbitration’s Final Award to UpHealth Holdings of more than $110 Million in Damages in Breach of Contract Lawsuit Involving the 2020 Purchase by UpHealth of Glocal Healthcare Systems
01/04/2024
DELRAY BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“UpHealth”) (OTC: UPHL), a leading provider of a full continuum of behavioral health solutions through the utilization of evidence-based treatments [...]
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
01/04/2024
-Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events -Phase 1a data demonstrated target engagement, a pharmacodynamic effect and effects on liver function -Initiating [...]
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
01/04/2024
- $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of warrants - Initial capital funds expansion of Phase 1b trial in severe alcohol-associated hepatitis and extends [...]
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2024
CLEVELAND, April 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved [...]
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
01/04/2024
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to [...]
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
01/04/2024
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront [...]

Pages